Sibrafiban

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sibrafiban
Sibrafiban structure.svg
Identifiers
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC20H28N4O6
Molar mass420.46 g/mol g·mol−1
3D model (JSmol)

Sibrafiban (Ro 48-3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI). On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients suffering from acute coronary syndrome. The development of sibrafiban was terminated.

See also[edit]